Dare Bioscience, Inc.
As of Oct 22, 2026, Dare Bioscience is in Stage 4, the downtrend phase, now in week 12 (since Jul 31, 2026). It closed at $0.65, 80.1% below its 52-week high and below its 200-day average, which is falling.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is DARE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
DARE among Biotechnology425th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …425 | DARE | Stage 4 · wk 12 | 15 | −19.2% |
Dare Bioscience: quick answers
What stage is Dare Bioscience in?
As of Oct 22, 2026, Dare Bioscience (DARE) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 31, 2026 and is in week 12. What the four stages mean
Is Dare Bioscience in an uptrend?
No. Dare Bioscience is in a Stage 4 downtrend. It trades 59.8% below its 200-day average, which is falling.
How far is Dare Bioscience from its 52-week high?
Dare Bioscience closed at $0.65 on Oct 22, 2026, 80.1% below its 52-week high of $3.27. Its 52-week low is $0.65.
How has Dare Bioscience performed over the past year?
As of Oct 22, 2026, Dare Bioscience is down 69.4% over the past year and down 66.6% so far in 2026.
Which sector and industry is Dare Bioscience in?
Dare Bioscience is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.